Daily Bitcoin and Crypto Analysis

Some markets move up, blind to bad news and unstoppable in their ascension. We have seen that throughout the last few years, but it has become more pronounced in the past couple of months. Something has changed and the momentum that characterised BTC throughout October and November seems to have cooled down.

Yesterday was a very interesting session for the crypto space. No, we did not breach new highs, test support levels or move dramatically one way or the other. We did have a scare and a bounce up. While traditional markets turned risk-off (S&P down 1%, Nasdaq down 2%, gold down 1.7%), one could’ve assumed some contagion to affect cryptocurrencies.

This year, Christmas day is on a Friday, which also happens to be the day a large amount of Bitcoin futures and options will expire. As we know, Bitcoin never sleeps and doesn't do public holidays. The December 25th expiry will likely be met with an unusually thin day of liquidity, which in turn could bring some Bitcoin sized volatility to Santa's stocking filler.

As they often do, markets switch from pessimism to optimism and vice-versa.

Bitcoin is beginning to form a new trading range at these elevated levels. As much as a rip-roaring rally is fun, a little time to acclimatize is a good thing. There would be no harm done if Bitcoin decided to track between $17,000 and $19,000 for a week or two — in fact, it would build a nice base for the next bout of price appreciation to blast off from.

The upward momentum we’ve seen recently seems to have slowed down somewhat, both in crypto and traditional assets.

This weekend’s trading session saw Bitcoin head back above $19,000, with muted trading volumes. Today, we have made little headway as the market takes a breath before its next advance to break the $20,000 barrier.

Over the Weekend… Guggenheim Partners filed an SEC amendment to allocate $500 million of their Macro Opportunities fund to Grayscale’s GBTC. This would provide the company an indirect means of exposure to crypto.

The US jobless claims might have fallen for the first time in months, but investor enthusiasm only fell somewhat. Pfizer’s supply chain problems mean that the initial distribution of vaccines might be halved.